Netherlands Pharmaceuticals & Healthcare Report Q2 2015

Jan 29, 2015 - Business Monitor International - 113 pages - USD $1,295
Abstract Table of Contents Request Details Related
Although the Dutch economy is expected to grow above the eurozone average over 2015 and 2016, the government will most likely continue to target the healthcare sector, resulting in further drug price cuts as it responds to rising healthcare costs from the demands of an increasing aging population. We uphold our view that the Netherlands ' generic and patented drug manufactures will continue to face difficult challenges and that overall market growth will be marginal over the coming years.

Headline Expenditure Projections
  • Pharmaceuticals: EUR5.92bn (USD7.93bn) in 2014 to EUR5.85bn (USD7.31bn) in 2015; -1.2% in local currency terms and -7.9% in US dollar terms.
  • Healthcare: EUR71.31bn (USD95.56bn) in 2014 to EUR72.55bn (USD90.69bn) in 2015; 1.7% in local currency terms and -5.1% in US dollar terms.
Risk/Reward Index

The Netherlands continues to rank in the lower half of BMI's Risk/Reward Index (RRI) for the 15 key Western European markets, ranking 11th in our ratings for Q215. The country has moved up a position from last quarter. At 65.9, its overall RRI score remains only slightly below the regional average of 67.4. While the country offers drugmakers a relatively low-risk operating environment, poor market prospects - due to pressures on pricing and reimbursement and the market's maturity - will continue to weigh down the country's overall standing.

Key Trends And Developments

December 2014

Dutch electronics company Philips has entered an agreement to acquire US-based medical device maker Volcano for USD1.2bn or USD18 a share, including debt. The offer represents a 57% premium on Volcano's closing price of USD11.49 on December 16. The acquisition aims to tap into the ageing population's need for more complex treatments, and will bolster Philips' line-up of medical imaging devices. The deal is expected to add to Philips' earnings per share by 2017, according to the company's statement. Volcano manufactures imaging catheters, which are used in...

The Netherlands Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Netherlands Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Netherlands pharmaceutical and healthcare industry.

Key Benefits
  • Benchmark BMI's pharmaceutical and healthcare market forecasts for Netherlands, to test other views - a key input for successful budgeting and strategic business planning in the Dutch pharmaceutical and healthcare market.
  • Target business opportunities and risks in the Dutch pharmaceutical and healthcare sector through our reviews of latest industry trends, regulatory changes and major deals, projects and investments in Netherlands.
  • Assess the activities, strategy and market position of your competitors using our company profiles (including SWOTs, KPIs and latest activity) and competitive landscape tables.
Coverage

BMI Industry View

An at-a-glance perspective on the latest regulatory developments, key forecast indicators and major corporate developments, covering the prescription, OTC and generics markets. The pharmaceuticals and healthcare SWOT outlines strategic factors that affect the basic assumptions underpinning BMI’s forecast analysis, and taken together with BMI’s political, economic and business environment SWOTs, it gives a complete overview of market climate.

BMI Industry Forecast Scenario

Industry forecasts to end-2019 for all key indicators, supported by explicit assumptions, plus analysis of key downside risks to the main forecasts:
  • Healthcare: Total healthcare expenditure (USDbn), healthcare expenditure (% of GDP), healthcare expenditure per capita (USD), hospital beds, doctors, and birth & mortality rates (all per ‘000 population).
  • Pharmaceutical Market: Drug expenditure in USDbn, % of GDP and per capita (USD).
  • Patented Drug Market: Prescription drug sales (USDbn & % of total sales).
  • Generic Drug Market: Generic product sales (USDbn), generic sales (% of total sales).
  • OTC Drug Market: OTC sales (USDbn & % of total sales).
  • Macroeconomic Forecasts: Nominal and real GDP, % real GDP growth, % private consumption growth, % industrial output growth, % consumer price index, % GDP price deflator, exports, imports, trade balance, current account balance, foreign direct investment, exchange rate against USD, government expenditure and external debt.
BMI’s Pharmaceuticals and Healthcare Risk Reward Index

BMI’s Risk Reward Index provides investors (both national and multinational) looking for opportunities in the region with a clear country-comparative assessment of the market’s risks and potential rewards. Each of the country markets are scored using a sophisticated model that includes more than 40 industry, economic and demographic data points to provide indices of highest to lowest appeal to investors, with each position explained.

Market Summary

A snapshot of key market characteristics, including total size of the pharmaceuticals and healthcare segments, growth drivers, leading therapeutic areas and the competitive landscape

Industry Developments

A focus on government healthcare reforms, epidemiological trends, mergers and acquisitions, product launches, market entries, FDI activity, R&D, biotechnology, clinical trials and supply chain issues.

Regulatory Regime

Details of the industry regulatory framework and key legislation covering the licensing of new products/services, pricing and reimbursements, intellectual property, taxation and advertising, as well as analysis of the overall regulatory burden.

Competitive Landscape

The competitive landscape section provides comparative company analyses and index by USD sales and % share of total sales – for the total pharmaceutical sector, as well as the OTC, generics and distribution sub-sectors.

Company Profiles*

Examines the competitive positioning and short- to medium-term business strategies of key industry players. Strategy is examined within the context of BMI’s industry forecasts, our macroeconomic views and our understanding of the wider competitive landscape to generate Company SWOT analyses. The latest financial and operating statistics and key company developments are also incorporated within the company profiles, enabling a full evaluation of recent company performance and future growth prospects.

*Company profiles are not available for every country. Those reports instead contain information on the current activities of prominent companies operating in the market.



Order This Report
FORMAT: PDF - Download Now with 3 Quarterly Updates $1,295 USD
LICENSE: Single-User
DELIVERY: Instant Download

EASY ORDERING
Once you’ve found the right report, click ‘order now’ and complete the checkout process using any major credit card, check or wire/bank transfer.

Need multi-user or enterprise license pricing? Contact us for a custom quote!
MC, Visa, AMEX, Diners, Discovery, JCB

The Fast Market Research Advantage
Only the Best
All of our research is sourced from the most trusted and established global analysts and consultancies

Client Focused
From start-ups to multinationals, we focus on providing the right research to our diverse client base

Shop Securely
Our US-based customer service team and eCommerce systems adhere to highest data security standards

Industry-leading Customer Support
Individualized assistance from our expert staff is never more than an email or phone call away


About the Publisher
Business Monitor International (BMI) offers a comprehensive range of products and services designed to help senior executives, analysts and researchers assess and better manage operating risks, and exploit business opportunities, across 175 markets. BMI offers three main areas of expertise: Country Risk BMI's country risk and macroeconomic forecast portfolio includes weekly financial market reports, monthly regional Monitors, and in-depth quarterly Business Forecast Reports. Industry Analysis BMI covers a total of 17 industry verticals through a portfolio of services, including Daily Alerts, monthly regional Insights, and in-depth quarterly Country Forecast Reports.